ICUINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

ICU MEDICAL INC/DE

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$161.24−1.75 (-1.07%)

Close on Oct 19, 2026

Market cap: $4.04B
P/E (TTM): 134.4
Dividend yield: –

ICU MEDICAL INC/DE income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Revenue	2,231	2,382	2,259	2,280	1,316	1,271	1,266	1,400	1,293	379	342	309	314	317	302	283	229	205	188
Cost of Revenue	1,409	1,557	1,519	1,582	825	810	794	830	867	178	161	158	159	160	160	154	123	115	110
Gross Profit	822	825	740	698	491	461	472	570	426	201	181	151	155	157	142	129	106	90	78
Research & Development	87	89	85	93	47	43	49	53	51	13	16	18	12	11	8.59	4.68	2.65	4.82	8.11
Selling, General & Admin	625	639	607	608	303	284	277	320	302	89	83	89	89	85	85	77	68	54	45
Advertising Expenses	–	–	–	–	0.20	0.20	0.10	0.60	0.20	0.10	0.20	0.10	0.30	0.20	0.10	0.10	–	–	–
Operating Expenses	779	782	717	741	368	363	365	540	439	118	112	112	103	95	77	81	71	58	54
Operating Income	43	43	23	-43	123	98	107	30	-13	83	69	39	52	61	65	48	35	31	25
Interest Expense	93	107	103	71	0.86	1.75	0.55	0.71	2.05	0.12	0.04	–	–	–	–	–	–	–	–
Interest & Investment Income	10	11	7.51	4.43	2.84	3.68	–	–	–	0.90	0.50	0.40	0.40	0.30	–	–	–	–	–
Income from Equity Investments	-1.19	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-0.23	-13	-5.91	-5.14	-2.04	-2.59	7.90	-6.67	-4.27	0.89	1.17	0.76	0.77	0.56	1.20	0.13	1.18	4.70	8.70
Merger & Restructuring Charges	30	20	6.71	9.70	-1.80	7.90	8.40	4.50	19	0.80	6.70	3.50	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	0	0	0	0	0	–	–	–	–	–
Gain (Loss) on Sale of Assets	-5.90	-2.52	-2.11	-2.01	-1.65	1.79	-13	-8.87	-3.78	-0.06	1.09	0	0	-0.21	14	0	0	-0.65	0.13
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.50	–	–	–	–
Pretax Income	4.36	-66	-78	–	–	97	115	22	51	85	70	40	53	62	66	48	37	36	33
Income Tax Expense	2.44	52	-49	-40	20	11	14	-6.42	-17	22	25	13	12	21	22	18	12	12	10
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	85	70	40	53	62	66	48	37	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	–	–	–	–	–	45	30	25	24	23
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	–	–	–	–	45	30	25	–	-0.07
Net Income	0.73	-118	-30	-74	103	87	101	29	69	63	45	26	40	41	45	30	–	–	–
EPS (Basic)(per share)	0.03	-4.83	-1.23	-3.11	4.86	4.16	4.90	1.41	3.50	3.90	2.84	1.72	2.75	2.90	3.23	2.20	1.70	1.72	1.62
EPS (Diluted)(per share)	0.03	-4.83	-1.23	-3.11	4.74	4.02	4.69	1.33	3.29	3.66	2.73	1.68	2.65	2.80	3.15	2.16	1.67	1.67	1.51
Shares Outstanding (Basic, Weighted)(shares)	25	24	24	24	21	21	21	20	20	16	16	15	15	14	14	14	15	14	14
Shares Outstanding (Diluted, Weighted)(shares)	25	24	24	24	22	22	22	22	21	17	16	16	15	15	14	14	15	15	15
EBITDA	244	262	252	192	213	184	184	104	53	102	87	58	71	80	84	65	51	46	36
Net Interest Income	-83	-96	-95	-66	1.98	1.92	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 39.1%
Operating margin: 3.3%
Net margin: 1.4%
Return on equity, FY2025: 0.0%

Financial strength

Current ratio: 2.43
Debt to equity: 0.57
Debt to assets: 31.0%
Cash to current liabilities: 59.9%

Valuation

P/E ratio: 134.4
Price to sales: 1.87
Price to book: 1.88
Dividend yield: –